Lynn Schuchter, MD, program leader for Penn's Melanoma Research Program says 2011 was the “year of melanoma,” one in which two important new agents were approved by the FDA (the first in over 40 years). It was in 2011, cancer research for melanoma began to make a significant difference for patients with advanced forms of melanoma. 2012 is emerging as a year in which researchers and clinicians are taking these new clinical approaches to the next...
